TabsDetailsBasic DetailsDate Posted: Monday, November 9, 2020Status: CompleteMedical Product: saxagliptin, sitagliptin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylureaHealth Outcome(s): diabetic ketoacidosisDescription: In this request we estimated the rate of diabetic ketoacidosis (DKA) among new users of Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas, saxagliptin, and sitagliptin in the Mini-Sentinel Distributed Database (MSDD). We distributed this request to 13 Data Partners on June 26, 2015. The study period included data from April 1, 2013 to March 31, 2015. Read More Deliverables (1)Mini-Sentinel Modular Program Report: Diabetic Ketoacidosis following Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors, Sulfonylureas, Saxagliptin, and Sitagliptin Use: A Descriptive AnalysisAdditional InformationAdditional DetailsFDA Center: CDERTime Period: April 1, 2013 - March 31, 2015Study Type: Modular ProgramAssessment Type: Safety AnalysesPopulation / Cohort: All individualsData Sources: Mini-Sentinel Distributed Dataset (MSDD)